Cross-Border Investigations Not at Cross Purposes and What We Can Learn From the Volkswagen Case
10 December 2015
This program will cover recent developments and law enforcement trends, risks, and organizational measures regarding cross-border investigations in Europe and the United States. One topic of discussion will be the Volkswagen investigation. Others will include:
- Enforcement trends in the United States and in Europe; enforcement actions and lessons learned (anti-bribery, money laundering, etc.)
- Substantive differences between the United States and EU (witness interviewing, reporting, privacy, safe harbor); comparison of U.S. and EU restrictions on investigations
- Comparison of treatment of attorney-client privilege
- Leniency program in European antitrust law
- The new decision of the European Court of Justice regarding safe harbor and its impact on cross-border investigations; executing responsive action and investigative plans
Registration Fee
EACC NY Member: Free
Non-EACC NY Member: $25
For more information, please contact John Vicars at [email protected].
Jonathan N. Halpern is the attorney responsible for this program.
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.